Compare Harley-Davidson Inc (HOG) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs IDEXX Laboratories, Inc. — how do they compare? Harley-Davidson Inc trades at $26.8 (market cap $2.78B), while IDEXX Laboratories, Inc. trades at $519.87 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 14.5× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.8% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 91 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| HOG | IDXX | |
|---|---|---|
Market Cap | $2.78B | $40.43B |
Volume | 2,966,389 | 692,164 |
Sector | Consumer Cyclical | Health |
52-Week High | $28.46 | $766.68 |
52-Week Low | $17.19 | $504.70 |
Typical Hold Time | 91 Days | 46 Days |
Enterprise Value | $3.20B | $41.32B |
Dividend Yield | 2.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.83, down 0.45% with a bullish technical signal and mixed earnings performance. The stock shows attractive valuation metrics with P/E of 14.86 and P/S of 0.72, while revenue has declined from $5.8B in 2022 to $4.5B in 2025. Recent Q2 2026 earnings beat expectations with $0.75 EPS versus $0.645 expected, though Q1 and Q4 2025 results missed targets. The company maintains a dividend payout with recent $0.1875 declaration.
Outlook remains cautious as revenue declines and margin compression continue, though valuation appears reasonable. Key risks include tariff exposure, competitive pressures, and ongoing revenue contraction. Analyst consensus targets $28.50 with mixed sentiment (27.78% Buy, 61.11% Hold). The stock offers value characteristics but faces fundamental headwinds requiring careful monitoring of turnaround execution.
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
